ArticleJournal of clinical pharmacology2026
Assessment of the Drug-Drug Interaction Potential of Lotiglipron (PF-07081532) with Midazolam, Omeprazole, Dabigatran, Rosuvastatin, and the Oral Contraceptives Levonorgestrel and Ethinyl Estradiol.
Article in Journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Two Phase 1 open-label studies were conducted in otherwise healthy participants, with BMI classified as overweight/obesity, to assess the potential of lotiglipron (a glucagon-like peptide-1 receptor agonist) as precipitant for pharmacokinetic (PK) drug-drug interactions (DDIs) when co-administered with substrates of cytochrome P450 (CYP) 3A (midazolam and oral contraceptive containing levonorgestrel/ethinyl estradiol [LE/EE]) and CYP2C19 (omeprazole) enzymes, and substrates of p-glycoprotein (dabigatran), breast cancer resistance protein and organic anion transporting polypeptide transporters (rosuvastatin). Potential PK DDI between semaglutide and midazolam was also assessed. Co-administration with lotiglipron led to modest dose-dependent decreases in midazolam area under the concentration-time curve (AUC) (up to 30%), no clinically relevant changes in exposures of oral contraceptive (LE/EE), substantial reductions in omeprazole AUC (up to 70%) and clinically relevant increases in rosuvastatin AUC (up to 2.3-fold). Upon co-administration with lotiglipron, maximum observed plasma concentration (C
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.